Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Diabetes, Obesity & Metabolism|November 25, 2016
Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort studyLotte M Knapen, Roy G P J de Jong, Johanna H M Driessen, et al.
BMC Cancer|March 3, 2022
Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancerStefanie D Krens, Nielka P van Erp, Stefanie L Groenland, et al.
BJC Reports|November 8, 2024
High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoidsKirti K Iyer, Dennis Poel, Anne Miggelenbrink, et al.
Therapeutic Drug Monitoring|July 21, 2015
The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 ActivityMarieke E B Welzen, Vincent O Dezentjé, Ron H N van Schaik, et al.
BMC Cancer|September 20, 2024
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocolJetty A M Weijers, Gerald W Verhaegh, G Lassche, et al.
British Journal of Clinical Pharmacology|November 14, 2014
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662Huixin Yu, Neeltje Steeghs, Jacqueline S L Kloth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2010
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinibAstrid A M van der Veldt, Karel Eechoute, Hans Gelderblom, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2014
Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)Marye J Boers-Sonderen, Carla M L van Herpen, Winette T A van der Graaf, et al.
Clinical Pharmacokinetics|September 27, 2024
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model EnsemblingBram C Agema, Tolra Kocher, Ayşenur B Öztürk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 TrialsOlivier Mir, Nathan Touati, Michela Lia, et al.
Pageof 11